Form 4: LAVA Therapeutics Director Sells Shares, Options

LAVA Therapeutics Director Karen J Wilson disposed of 10,000 common shares and 33,390 share options as part of a pre-arranged purchase agreement with XOMA Royalty Corporation.

Summary

• Karen J Wilson, a Director of LAVA Therapeutics NV (LVTX), reported the disposition of securities.
• The transaction occurred on November 13, 2025, and was made pursuant to a Rule 10b5-1(c) plan.
• Wilson disposed of 10,000 Common Shares.
• Wilson also disposed of 33,390 Share Options with an exercise price of $0.93.
• The dispositions were made under a Purchase Agreement dated August 3, 2025, between LAVA Therapeutics NV and XOMA Royalty Corporation.
• For the Common Shares, the consideration was $1.04 in cash per share plus one non-transferable contingent value right (CVR) per share.
• For the Share Options, the consideration was cash equal to the excess of $1.04 over the $0.93 exercise price per share, multiplied by the total number of shares underlying the option, plus one CVR per share underlying the option.

Sentiment

Score: 5

Explanation: The filing reports a pre-arranged insider transaction (Rule 10b5-1(c) plan) as part of a specific Purchase Agreement, making it a neutral event in terms of immediate sentiment. The disposition of shares by a director is offset by the pre-planned nature and the inclusion of CVRs.

Positives

• The inclusion of Contingent Value Rights (CVRs) in the consideration provides potential future upside for the seller based on specific milestones or events.

Negatives

• A director's disposition of a significant number of shares and options could be perceived negatively by some investors, although this was part of a pre-arranged agreement.

Future Outlook

The filing does not provide a future outlook for the company, focusing solely on the reported insider transaction.

Industry Context

This Form 4 reports an insider transaction, specifically a director's disposition of securities, which is a routine disclosure. The underlying Purchase Agreement with XOMA Royalty Corporation suggests a strategic transaction that led to these dispositions, potentially related to a broader corporate event or financing, though details are not in this specific filing.

Comparison to Industry Standards

• This Form 4 reports a standard insider transaction. Without details of the underlying Purchase Agreement, it is not possible to compare the terms of the disposition (e.g., the $1.04 cash price and CVRs) to industry benchmarks or similar transactions by comparable companies. The transaction itself is compliant with SEC regulations for insider reporting.

Stakeholder Impact

• Shareholders: The disposition of shares by a director, even if pre-arranged, could lead to questions regarding management's confidence, though the CVRs offer potential future value.
• Reporting Person (Karen J Wilson): Received cash and contingent value rights for her disposed shares and options.

Key Dates

Keywords

LVTX, insider transaction, director share sale, stock options, contingent value rights, XOMA Royalty Corporation, Rule 10b5-1 plan